Real-World Clinical Outcomes In Patients Receiving Cyclin-Dependent Kinase 4/6 Inhibitors (Icdk 4/6) For Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (Hr+/Her2-) Metastatic Breast Cancer In Mexico.

Benigno Rodriguez,Lorena López Zepeda,Alejandro Noguez-Ramos,Daniela Vazquez Juarez,Christian Patricio Camacho Limas,Gabriela Olivia Regalado Porras,Ivonne Salcedo,Samuel Rivera,Alvaro Aguayo,Yazmin Carolina Blanco Vazquez, Angel Azael Lopez Galindo,Daniela Shveid Gerson,Fernando Perez-Zincer,Juan Alberto Serrano,José Fabián Martínez-Herrera,Guillermo Olivares,Alberto Villalobos, Cesar Gonzalez De Leon,Raquel Gerson

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 0|浏览17

暂无评分

摘要

e13053Background: Breast cancer was the second most common malignant tumor diagnosed in 2018 worldwide, and the main cause of cancer death in women. In Mexico is the leading cause of cancer deaths,...

查看译文

关键词

Metastatic Breast Cancer,CDK4/6 Inhibitors,Breast Cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要